Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1998

View Archived Issues

Entropin concentrates its efforts on bringing Esterom to market

Inflazyme advances development of asthma therapeutic

Idec Pharmaceuticals: Q3 1998 highlights

Amylin: Q3 1998 highlights

Optimal dosing regimen for 5G1.1-SC in heart attack under evaluation in phase I trial

Connetics: Q3 1998 highlights

Novel isoquinoline anticonvulsants in development at SB

Korean laboratory prepares new series of TNF-alpha inhibitors

Meiji Seika discloses new neuroprotective substance isolated from fungus

Potent and selective COX-2 inhibitors from Merck Frosst useful for inflammation

New immunosuppressants in the pipeline at Kyowa Hakko

Otsuka NO inhibitor series particularly useful in asthma and atopic dermatitis

Schering-Plough describes SAR leading to discovery of potent cholesterol absorption inhibitor

Preclinical study results explain why TMK-688 does not induce drowsiness

Banyu seeks licensees for new parenteral carbapenems

Potential new antithrombotic agent profiled, structure revealed

GlyT-1 technology forms the basis of Allelix and Janssen neuropsychiatric collaboration

First Neoral equivalent cleared by FDA

New agreement between Pharmacopeia and Schering-Plough expands R&D collaboration

European research group focuses on TTD non-nucleoside reverse transcriptase inhibitors

Adoptive immunotherapy of cancer with HSPs covered by U.S. patent

Alza focuses on urology products; licenses Urispas

Medtronic seeks to become leader in neurological and spinal medical technologies

GenVec receives expanded patent coverage in field of gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...